Sun Pharma Advanced Research Company cash flow

Latest FY26
Cash from operations
−₹239cr−₹360 cr in FY25
Capital spending
₹23.8cr+130.5% on FY25
Free cash flow
−₹263cr−₹371 cr in FY25
Cash from financing
₹261cr+31.2% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—10.212.412.511.8
—34.19.01.77.6
—−10.3−0.7−25.5−7.6
—7.40.92.1—
—−0.2−0.01.5—
Changes in working capital
—8.3−0.415.2−5.0
—0.0−1.1−3.2—
—−1,8593.4−63.110.4
—−18.2−29.3−5.976.7
—−8.0−16.922.7—
—11.9−3.63.8—
Cash from operating activities
1,5841,553−343−387—
—−1,823−26.3−38.3—
—−270−369−425—
—−31.6−8.84.1—
—−239−360−429−69.1
Cash from investing activities
—23.810.326.515.4
—0.30.60.50.5
—0.02.9284—
—0.014.622.41.9
—0.0150111—
—−23.5158392−548
Cash from financing activities
—2,11658064.4225
—1,81836917.5—
—2.43.52.93.4
—34.28.41.67.7
—26119942.4617
—−0.9−3.44.8—
—0.10.00.0—
—−0.8−3.44.8−0.6
——2.05.30.6
Reference items
1,6171,599−323−402—
84.7%85.1%−450.2%−532.2%—
−263−263−371−456−84.5
—1.1−168−485—
−₹8.09−₹8.09−₹11.42−₹14.04−₹2.60
—−0.15×1.05×1.11×—
—−31.6−8.84.1—
—34.28.41.67.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SPARC₹172.50

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹5,598 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation11.812.512.410.2—
+ Finance Costs7.61.79.034.1—
+ Interest Income-7.6-25.5-0.7-10.3—
+ Unrealised FX (Gain) / Loss—2.10.97.4—
+ Other Non-cash Items—1.5-0.0-0.2—
Changes in Working Capital
+ Trade Receivables — Current-5.015.2-0.48.3—
+ Other Financial Assets — Current—-3.2-1.10.0—
+ Other Current Assets10.4-63.13.4-1,858.6—
+ Trade Payables — Current76.7-5.9-29.3-18.2—
+ Other Current Liabilities—22.7-16.9-8.0—
+ Provisions — Current—3.8-3.611.9—
Cash from Operating Activities
Profit Before Tax (per I/S)—-386.8-342.81,553.01,584.2
+ Total Adjustments (incl. Working Capital)—-38.3-26.3-1,823.4—
Cash from Operations (pre-tax)—-425.1-369.1-270.4—
+ Income Taxes Paid—4.1-8.8-31.6—
Cash from Operating Activities-69.1-429.2-360.3-238.8—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)15.426.510.323.8—
+ Disp of Fixed Assets0.50.50.60.3—
+ Disp of Investment Property—284.22.90.0—
+ Interest Received — Investing1.922.414.60.0—
+ Other Inflows / (Outflows) — Investing—111.0150.00.0—
Cash from Investing Activities-548.3391.5157.7-23.5—
Cash from Financing Activities
+ Proceeds from Borrowings224.564.4580.22,115.8—
+ Repayment of Borrowings—17.5369.01,817.9—
+ Payment of Lease Liabilities3.42.93.52.4—
+ Interest Paid7.71.68.434.2—
Cash from Financing Activities616.842.4199.3261.4—
Net Changes in Cash (pre-FX)—4.8-3.4-0.9—
+ Effect of FX Rate Changes on Cash—0.00.00.1—
Net Changes in Cash-0.64.8-3.4-0.8—
Closing Cash0.65.32.0——
Reference Items
EBITDA—-402.1-323.11,598.81,616.8
EBITDA Margin %—-532.23-450.2485.0884.68
Free Cash Flow (CFO − Capex)-84.5-455.7-370.6-262.6-262.6
Free Cash Flow to Equity—-485.3-167.91.1—
Free Cash Flow per Basic Share-2.60-14.04-11.42-8.09-8.09
Cash Flow to Net Income—1.111.05-0.15—
Cash Paid for Taxes—4.1-8.8-31.6—
Cash Paid for Interest7.71.68.434.2—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.